New York University

Laura M Cox

Martin J Blaser

Ilseung Cho

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial generaand, including their species() and(), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble eitherspp. orspp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of ROR&#x3b3;T, IL-17A, IL-17F, RegIII&#x3b3;, Relm&#x3b2;, and Def&#x3b2;), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).

Probiotic compositions for improving metabolism and immunity

Card reader with keyboard

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant(MRSA),vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

Growing community of inventors

Brookline, MA, United States of America

Laura M Cox